The first clinical trial of a lentiviral vector highlights the promise of this new class of gene-therapy vector.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Engineering fusogenic molecules to achieve targeted transduction of enveloped lentiviral vectors
Journal of Biological Engineering Open Access 02 June 2009
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Podsakoff, G.M., Engel, B. & Kohn, D.B. Biol. Blood Marrow Transplant. 11, 972–976 (2005).
Levine, B.L. et al. Proc. Natl. Acad. Sci. USA 103, 17372–17377 (2006).
Naldini, L. et al. Science 272, 263–267 (1996).
Zufferey, R. et al. Nat. Biotechnol. 15, 871–875 (1997).
May, C. et al. Nature 406, 82–86 (2000).
Hacein-Bey-Abina, S. et al. Science 302, 415–419 (2003).
Bushman, F. et al. Nat. Rev. Microbiol. 3, 848–858 (2005).
Montini, E. et al. Nat. Biotechnol. 24, 687–696 (2006).
Humeau, L.M. et al. Mol. Ther. 9, 902–913 (2004).
Dropulic, B., Hermankova, M. & Pitha, P.M. Proc. Natl. Acad. Sci. USA 93, 11103–11108 (1996).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kohn, D. Lentiviral vectors ready for prime-time. Nat Biotechnol 25, 65–66 (2007). https://doi.org/10.1038/nbt0107-65
Issue Date:
DOI: https://doi.org/10.1038/nbt0107-65
This article is cited by
-
Gene Therapy for Heart Failure: Where Do We Stand?
Current Cardiology Reports (2013)
-
The use of cell-delivered gene therapy for the treatment of HIV/AIDS
Immunologic Research (2010)
-
Engineering fusogenic molecules to achieve targeted transduction of enveloped lentiviral vectors
Journal of Biological Engineering (2009)
-
Lentiviral gene transfer to reduce atherosclerosis progression by long-term CC-chemokine inhibition
Gene Therapy (2009)
-
Cell Type-Specific Targeting with Surface-Engineered Lentiviral Vectors Co-displaying OKT3 Antibody and Fusogenic Molecule
Pharmaceutical Research (2009)